Xcout Intel
Paratek Pharmaceuticals competitors & alternatives
The 12 closest competitors and alternatives to Paratek Pharmaceuticals among pharmaceuticals companies — ranked by similarity to what Paratek Pharmaceuticals actually does, not by market-cap band.
Subscribe to see Paratek Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Paratek Pharmaceuticals
Paratek Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for complex medical conditions, focusing on infectious diseases and antimicrobial resistance. The company's product portfolio includes NUZYRA, an antibiotic for bacterial infections, and XHANCE, a nasal spray for chronic rhinosinusitis. These treatments are designed to serve adult patients with significant unmet medical needs.
Paratek Pharmaceuticals at a glance
Paratek Pharmaceuticals is a pharmaceuticals company headquartered in United States. Xcout tracks 9 named people at Paratek Pharmaceuticals, including Evan Loh, M.D. (Chief Executive Officer). Xcout recorded 40 job postings from Paratek Pharmaceuticals in the last 90 days.
Paratek Pharmaceuticals leadership
- Evan Loh, M.D.Chief Executive Officer
- Adam WoodrowPresident and Chief Commercial Officer
- Chris BostromChief Financial Officer
- Jonathan LightChief Legal Officer, Corporate Secretary, and Corporate Compliance Officer
- Karen McGrathChief People Officer
- Randy BrennerChief Development and Regulatory Officer
3 more named people on record for Paratek Pharmaceuticals, with roles, board committees and tenure — see the full roster →
Hiring at Paratek Pharmaceuticals
Xcout recorded 40 job postings from Paratek Pharmaceuticals in the last 90 days, from a hiring record Xcout has kept since August 2026.
The weekly hiring trend, the roles and locations behind it — see Paratek Pharmaceuticals's hiring signals →
Top 12 Paratek Pharmaceuticals competitors
Ranked by semantic similarity — how close each company is to Paratek Pharmaceuticals by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology, Drug Discovery
QureTech Bio is a biotechnology company that develops treatments to defeat bacterial virulence and restore antibiotic susceptibility, specifically targeting drug-resistant infections such as Staphylococcus aureus. The company serves the pharmaceutical and healthcare sectors by advancing novel antibacterial portfolios and seeking partnership opportunities.
Similar pharmaceuticals company
Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company based in Oklahoma City, Oklahoma, developing orally active compounds that restore the efficacy of existing antibiotics.
Similar pharmaceuticals company
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Similar pharmaceuticals company
Venatorx Pharmaceuticals, Inc. is a pharmaceutical manufacturing company based in Malvern, Pennsylvania, focused on the discovery and development of novel anti-infective treatments.
Pharma
AiCuris Anti-infective Cures AG is a biopharmaceutical company headquartered in Wuppertal, Germany. The company specializes in the research and development of innovative, life-saving anti-infective therapies designed to address critical needs in immunocompromised patients.
Similar pharmaceuticals company
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.
Similar pharmaceuticals company
Basilea Pharmaceutica Ltd is a pharmaceutical company focused on developing and commercializing medicines, particularly anti-infective treatments such as antibiotics and antifungals. It serves healthcare providers and patients, primarily in markets where its products are approved and distributed.
Similar pharmaceuticals company
Shanghai MicuRx Pharmaceutical Co., Ltd. is a China-based biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections, including drug-resistant infections. It developed contezolid (MRX-I), an oxazolidinone antibiotic intended for treatment of resistant Gram-positive bacterial infections, serving hospitals and infectious-disease patients.
Similar pharmaceuticals company
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Similar pharmaceuticals company
Protez Pharmaceuticals is a pharmaceutical and medical research company founded in 2003 and focused on the discovery and development of novel injectable and oral small molecule antibiotics for hospital-based, difficult-to-treat infections. The company was acquired by Novartis AG in June 2008.
Similar pharmaceuticals company
Recreo Pharmaceuticals LLC is a healthcare company focused on developing and testing antibiotics to combat antibiotic resistance and improve patient health. The firm monitors industry trends and medical technology to advance its drug development initiatives.
Similar pharmaceuticals company
Chiesi Farmaceutici is a global biopharmaceutical group that researches, develops, and commercializes therapeutic solutions for patients. The company focuses primarily on respiratory health, rare diseases, and specialty care.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Paratek Pharmaceuticals and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Paratek Pharmaceuticalsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →